Upside, Downside Movers in the A.M.
Upside:
-IMVT +23% (earnings, color)
-POET +15% (Marex Securities Products builds 6% stake in POET)
-TATT +14% (earnings, color)
-EGHT +12% (earnings, guidance)
-RRGB +10% (earnings, guidance)
-IBRX +8.3% (US FDA Accepts sBLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease)
-CAVA +7.7% (earnings, guidance)
-AMC +5.1% (CEO Adam Aron bought 250K shares at $1.377/shr)
-MRVL +4.9% (multiple broker price target raises)
-STM +4.5% (Euro semi name strength)
-LPG +3.9% (earnings, color)
-MU +3.9% (momentum amid potential memory chip shortage)
-TJX +3.8% (earnings, guidance)
-VFC +3.4% (earnings, guidance)
-PSNL +3.3% (Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company’s NeXT Personal minimal residual disease (MRD) test)
-TOL +3.3% (earnings, guidance)
-ASML +2.9% (Euro semi name strength)
-SNDK +2.4% (memory stock strength with rising memory price concerns)
-DMAC +2.3% (announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial)
Downside:
-VIAV -8.7% (prices 11.1M shares at $45.00/shr)
-NWL -2.6% (Morgan Stanley Cuts NWL to Underweight from Equal Weight, price target: $3.50)
-HAS -2.2% (earnings, guidance)
-LOW -2.1% (earnings, guidance)
Positions: None.
